Eczema is more than dry skin. For patients with moderate to severe atopic dermatitis, the constant itching, sleep disruption, and visible inflammation can be exhausting and isolating. New biologic treatments improve symptoms meaningfully for many patients who have not responded to topical therapy.
Atopic dermatitis (eczema) is a chronic Type 2 inflammatory skin disease characterized by intensely itchy, inflamed patches of skin. It commonly begins in childhood but can present or worsen in adulthood, sometimes dramatically. Many patients have other atopic conditions — asthma, allergic rhinitis, food allergies, eosinophilic esophagitis — reflecting a shared underlying inflammatory biology.
Adult-onset and adult-persistent atopic dermatitis is increasingly recognized. Severity is variable: mild disease can be managed with moisturizers and intermittent topical anti-inflammatories, while moderate to severe disease can profoundly affect sleep, mood, work productivity, and self-image. The biologic era has substantially expanded options for patients with moderate to severe disease.
Diagnosis is clinical based on the appearance, distribution, and pattern of skin involvement. Severity is assessed using validated scoring tools, and the impact on quality of life is documented. Laboratory evaluation typically includes total IgE and eosinophil count for biologic candidacy, and screening for trigger sensitivities when relevant.
Coordination with dermatology is common, particularly when topical regimens need optimization or when other skin conditions are on the differential.
Skin care optimization is foundational — appropriate moisturization, gentle cleansing, identification and avoidance of triggers. Topical anti-inflammatory therapy is reviewed and adjusted. For moderate to severe disease that does not respond adequately to topical care, biologic therapy with dupilumab (Dupixent) is FDA-approved for adolescent and adult atopic dermatitis. Many patients describe meaningful improvement in itch and skin appearance within weeks of starting treatment, though individual response varies.
Additional newer therapies are available for patients who do not respond adequately to dupilumab or for whom it is not appropriate.
A first visit takes a complete history of your eczema, prior treatments, and any associated atopic conditions. Severity is assessed and quality-of-life impact discussed. For biologic candidacy, basic labs are ordered. Prior authorization is handled in-house.
Every patient’s situation is different, but the decision logic for atopic dermatitis generally follows these steps. This is not a script — it is a structure that gets adapted to each patient’s history, findings, and goals.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes and does not substitute for clinical judgment or direct medical advice. Treatment decisions are individualized based on your full history, examination, and laboratory findings. If you have an emergency, call 911.